Decision to list needles and syringes products supplied by B. Braun New Zealand Pty Limited
Source: Pharmac What we are doing We are pleased to announce a listing agreement with B. Braun New Zealand Pty Limited (“B. Braun”) for the supply of needles and syringes products to DHBs. In summary this will result in: B. Braun’s needles and syringes products being listed on the Pharmaceutical Schedule from 1 March 2019 under […]
Read More →Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit and hyperactivity disorder
Source: Pharmac What will the effect be? For Patients Modafinil (Modavigil) There will be no change for patients as this product will continue to be fully funded subject to the same restrictions as it is now. Methylphenidate extended-release tablets (Methylphenidate ER – Teva) An additional funded brand will be available for patients who meet the […]
Read More →Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
Source: Pharmac What we’re doing We’re pleased to announce PHARMAC’s decision to approve a multiproduct agreement with Merck Sharpe & Dohme (MSD). This will result in the listing of a new, once-daily presentation of raltegravir for the treatment of HIV, once it is registered with Medsafe, as well as changes to the contractual arrangements for […]
Read More →Decision to list ostomy products supplied by Omnigon Pty Ltd
Source: Pharmac Detail about this decision In May 2018, PHARMAC issued a request for proposals (“RFP”) for the supply of urology, ostomy and continence products to DHBs. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule. After evaluating Omnigon’s proposal, and consulting on the provisional agreement reached, PHARMAC has decided […]
Read More →December 2018 tender notification
Source: Pharmac 20 December 2018 PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2017/18 Invitation to Tender, dated 2 November 2017. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject […]
Read More →Decision to list medical devices supplied by Medtronic
Source: Pharmac Detail about this decision In 2017 PHARMAC issued a Requests for Proposals (“RFP”) for needles and syringes. The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule. After completing the RFP evaluation processes and consulting on the provisional Agreement reached with Medtronic, PHARMAC has decided to list Medtronic’s range of […]
Read More →Proposal to amend the distribution and access criteria for dasatinib (Sprycel)
Source: Pharmac PHARMAC is seeking feedback on a proposal to amend the distribution arrangements and access criteria for the funding of dasatinib (Sprycel) tablets for chronic myeloid leukaemia (CML) from 1 May 2019. In summary: Dasatinib would be funded subject to a standard Special Authority managed by the Ministry of Health and there would no […]
Read More →Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis
Source: Pharmac What we’re doing We are pleased to announce a decision to fund a new treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret) from 1 February 2019, and to widen access to adalimumab (Humira) for patients with psoriasis from 1 July 2019, through an agreement with AbbVie Ltd. In summary, this decision will […]
Read More →PHARMAC funding decision gives Kiwis with hepatitis C access to a potential cure
Source: Pharmac Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February 2019, after PHARMAC funds a new treatment. The medicine known as Maviret (glecaprevir and pibrentasvir) can be prescribed to people with hepatitis C regardless of the type of hepatitis C virus they have. Director of Operations, Lisa […]
Read More →Decision in relation to infliximab, tocilizumab and rituximab
Source: Pharmac Who we think will be most interested Anyone with an interest in the supply, provision or use of infliximab, rituximab or tocilizumab within DHB hospitals. As this proposal is an administrative change, we expect that patients should not notice any differences in the way they access these treatments. Detail about this decision We […]
Read More →Update for the 2018/19 Invitation to Tender – 12 December 2018
Source: Pharmac Amendment to line items Line items have been amended for the following products (change in italics): Busulfan – tab 2 mg: tender extended to include listing in community and hospital settings Mercaptopurine – tab 50 mg: tender extended to include listing in community and hospital settings Methotrexate – inj 25 mg per ml, […]
Read More →Decision to list haemodialysis products supplied by BSN Medical Limited
Source: Pharmac What we are doing We are pleased to announce the approval of a listing agreement for a range of haemodialysis products with BSN Medical Limited (“BSN Medical”). In summary this will result in: Listing 10 Haemodialysis procedure packs from BSN Medical in Part III of Section H of the Pharmaceutical Schedule from 1 February […]
Read More →Decision to list a new brand of iron polymaltose (Ferrosig)
Source: Pharmac Detail about this decision The currently listed brand of iron polymaltose, Ferrum H (supplied by Vifor), is being discontinued and will be delisted from the Pharmaceutical Schedule on 1 April 2019. To ensure continuous supply of iron polymaltose, PHARMAC has reached an agreement with Sigma Healthcare for ongoing supply of its brand of iron […]
Read More →Decision to list Interventional Radiology products supplied by Edwards Lifesciences (New Zealand) Limited
Source: Pharmac Detail about this decision In September 2017 PHARMAC issued a Request for Proposals (“RFP”) for interventional radiology products for non-exclusive national agreements for listing on the Pharmaceutical Schedule. After completing the RFP evaluation, and consulting on the provisional agreement reached with Edwards, PHARMAC has decided to list Edward’s ranges of Interventional Radiology Products […]
Read More →Proposal to open access to atomoxetine and change funded brand
Source: Pharmac What we’re proposing PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the funded brand of atomoxetine from Strattera to a brand supplied by Generic Partners (NZ) Limited. The Generic Partners brand of atomoxetine would be listed from 1 July 2019, and the community and hospital funding […]
Read More →Proposal to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
Source: Pharmac What we’re proposing PHARMAC is seeking your feedback on a multiproduct proposal with Merck Sharpe & Dohme (MSD). The proposal would list a new, once-daily presentation of raltegravir for the treatment of HIV, as well as make changes to the contractual arrangements for the currently funded presentation of raltegravir and for posaconazole. Consultation […]
Read More →Decision to remove funding restrictions for alendronate 70 mg products, decrease price, and award sole supply
Source: Pharmac What we are doing We’re pleased to announce that the funding restrictions on alendronate 70 mg products will be removed from 1 February 2019. At the same time, the price and subsidy of these products will decrease. The Fosamax and Fosamax Plus brands, supplied by Merck Sharp and Dohme (MSD), will remain the […]
Read More →Proposal to list ostomy products supplied by Omnigon Pty Ltd
Source: Pharmac What we are proposing PHARMAC is seeking feedback on a proposal to list a range of Ostomy Products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019, through a listing agreement with Omnigon Pty Ltd (“Omnigon”). Consultation closes at 4pm on Friday, 14 December 2018 and feedback can […]
Read More →Proposal to list medical devices supplied by Medtronic New Zealand Limited
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to list a range of needles and syringes in Part III of Section H of the Pharmaceutical Schedule from 1 March 2019, through a provisional agreement with Medtronic New Zealand Limited (“Medtronic”). Consultation closes at 4pm on Friday, 14 December 2018 and feedback […]
Read More →Notice of Information: No further RFPs to be released in 2018
Source: Pharmac 21 November 2018 PHARMAC will not be releasing any further Requests for Proposals (RFPs) in 2018. As we approach the end of the year we recognize that some suppliers are preparing submissions to several RFPs, and appreciate the significant efforts that this requires. While PHARMAC’s Annual Procurement Plan (updated in October 2018) indicated […]
Read More →